Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 325 of 344 entries
View as:

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Phase: N/A Priority: Normal
NCT ID: NCT05029973 Org: User:
Start: 05/10/21 End: 11/10/23 Due: 11/10/24

Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01635465 Org: User:
Start: 11/30/16 End: 12/31/16 Due: 12/31/17

Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05522985 Org: User:
Start: 11/07/21 End: 11/07/24 Due: 11/07/25

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03355612 Org: User:
Start: 12/20/17 End: 12/20/25 Due: 12/20/26

The Importance of Thymus Anatomy to the Radical Resection of Thyroid Cancer Surgery and the Protection of Parathyroid Function

Phase: N/A Priority: Normal
NCT ID: NCT06851260 Org: User:
Start: 02/20/25 End: 03/30/26 Due: 03/30/27

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Phase: N/A Priority: Normal
NCT ID: NCT06363734 Org: User:
Start: 04/09/24 End: 12/31/26 Due: 12/31/27

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

Phase: N/A Priority: Normal
NCT ID: NCT05651672 Org: User:
Start: 12/02/22 End: 12/31/26 Due: 12/31/27

Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07033143 Org: User:
Start: 07/31/25 End: 07/31/29 Due: 07/31/30

Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06814158 Org: User:
Start: 03/01/25 End: 12/31/26 Due: 12/31/27

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Phase: N/A Priority: Normal
NCT ID: NCT04965831 Org: User:
Start: 08/01/21 End: 05/01/26 Due: 05/01/27

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04903652 Org: User:
Start: 01/01/21 End: 02/06/22 Due: 02/06/23

the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake

Phase: N/A Priority: Normal
NCT ID: NCT01873014 Org: User:
Start: 06/30/12 End: 12/31/16 Due: 12/31/17

Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04813523 Org: User:
Start: 04/01/21 End: 03/31/24 Due: 03/31/25

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05356351 Org: User:
Start: 05/01/22 End: 07/30/27 Due: 07/30/28

Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation Procedures

Phase: N/A Priority: Normal
NCT ID: NCT06581107 Org: User:
Start: 09/15/24 End: 02/28/25 Due: 02/28/26

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Phase: N/A Priority: Normal
NCT ID: NCT04526028 Org: User:
Start: 09/13/19 End: 05/31/23 Due: 05/31/24

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03121846 Org: User:
Start: 05/01/17 End: 05/01/19 Due: 05/01/20

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06454448 Org: User:
Start: 06/15/24 End: 11/30/26 Due: 11/30/27

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Phase: N/A Priority: Normal
NCT ID: NCT03671265 Org: User:
Start: 09/17/18 End: 09/01/21 Due: 09/01/22

Study on the Peristaltic Direction of GI Anastomosis in Roux-en-Y Reconstruction

Phase: N/A Priority: Normal
NCT ID: NCT04801459 Org: User:
Start: 04/02/21 End: 03/31/24 Due: 03/31/25

Almonertinib With Chemotherapy in mEGFR NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04646824 Org: User:
Start: 11/19/20 End: 11/25/22 Due: 11/25/23

Chemotherapy Combined With Apatinib and PD-1 Antibody

Phase: N/A Priority: Normal
NCT ID: NCT05025033 Org: User:
Start: 05/30/19 End: 04/30/22 Due: 04/30/23

Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06867432 Org: User:
Start: 03/01/25 End: 03/01/27 Due: 03/01/28

Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04354662 Org: User:
Start: 09/26/19 End: 06/30/24 Due: 06/30/25

A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05828875 Org: User:
Start: 08/01/23 End: 07/01/24 Due: 07/01/25